JSAM
JANX icon

J. Safra Asset Management’s Janux Therapeutics JANX Stock Holding History

J. Safra Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-86
Closed -$2.1K – 647
2025
Q3 		$2.1K Hold
86
– – ﹤0.01% 396
2025
Q2 		$1.99K Buy
86
+20
+30% +$527 ﹤0.01% 349
2025
Q1 		$1.78K Buy
66
+56
+560% +$2.11K ﹤0.01% 328
2024
Q4 		$525 Buy
10
+3
+43% +$159 ﹤0.01% 324
2024
Q3 		$324 Buy
+7
New +$305 ﹤0.01% 296

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

J. Safra Asset Management's JANX Position: Q4 2025 in Review

J. Safra Asset Management sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 86 shares — an estimated $2.1K sold.

J. Safra Asset Management first reported a position in JANX in Q3 2024 and held it in 5 quarters. The position peaked at $2.1K in Q3 2025. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • J. Safra Asset Management reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • J. Safra Asset Management sold 86 Janux Therapeutics shares in Q4 2025, an estimated $2.1K.
  • J. Safra Asset Management first reported a position in Janux Therapeutics in Q3 2024 and held it in 5 quarters.
  • J. Safra Asset Management's Janux Therapeutics position peaked at $2.1K in Q3 2025.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on J. Safra Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.